Spots Global Cancer Trial Database for A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Official Title: A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Study ID: NCT01379534
Interventions
Study Description
Brief Summary: This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of South Alabama / Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, United States
St. Jude Heritage Medical Group St Jude, Fullerton, California, United States
USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, United States
Cedars Sinai Medical Center TKI258A2211 (SC), Los Angeles, California, United States
University of California at Los Angeles UCLA 3, Los Angeles, California, United States
Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States
Florida Hospital Cancer Institute FL Hosp, Orlando, Florida, United States
Indiana University Health Goshen Center for Cancer IU Simon Cancer, Indianapolis, Indiana, United States
University of Iowa Hospitals & Clinics SC, Iowa City, Iowa, United States
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States
Hope A Woman's Cancer Center, Asheville, North Carolina, United States
Duke University Medical Center Duke3, Durham, North Carolina, United States
Community Oncology Research Network, Chattanooga, Tennessee, United States
The West Clinic SC, Memphis, Tennessee, United States
Texas Oncology, P.A. Austin, Bedford, Texas, United States
Texas Oncology, P.A. Tex Onc (3), Bedford, Texas, United States
Texas Oncology, P.A. SC, Fort Worth, Texas, United States
South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, United States
Virginia Oncology Associates VOA - Lake Wright, *see Various Departments*, Virginia, United States
Cancer Care Northwest SC, Spokane, Washington, United States
Novartis Investigative Site, Belo Horizonte, MG, Brazil
Novartis Investigative Site, Porto Alegre, RS, Brazil
Novartis Investigative Site, Ribeirao Preto, SP, Brazil
Novartis Investigative Site, Genova, GE, Italy
Novartis Investigative Site, Monza, MB, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Pisa, PI, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Candiolo, TO, Italy
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Grafton, Auckland, , New Zealand
Novartis Investigative Site, Cordoba, Andalucia, Spain
Novartis Investigative Site, Málaga, Andalucia, Spain
Novartis Investigative Site, Oviedo, Asturias, Spain
Novartis Investigative Site, Sabadell, Barcelona, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Majadahonda, Madrid, Spain
Novartis Investigative Site, Murcia, , Spain
Novartis Investigative Site, Glasgow, , United Kingdom
Novartis Investigative Site, Leeds, , United Kingdom
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, Nottingham, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
